Tailored drug combo aims to boost breast cancer remission before surgery

NCT ID NCT07300215

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Bengbu Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a personalized approach for women with early-stage HR+/HER2+ breast cancer. After two cycles of standard therapy, patients who respond well continue the same treatment, while those who do not switch to a combination of targeted therapy and hormone-blocking drugs. The goal is to increase the rate of complete tumor disappearance before surgery. The study will enroll 60 participants and track tumor response and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: individualized neoadjuvant treatment (TCbHP, trastuzumab dual-target, exemestane, palbociclib)
What this could lead to: If successful, this approach could increase the rate of complete tumor disappearance before surgery, potentially improving long-term outcomes for patients with this specific breast cancer type.
What could go wrong: This is a small, early-phase exploratory study with only 60 participants, so results may not apply broadly. The treatment involves multiple drugs, which could increase side effects, and the strategy may not improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.